[EN] CARBAMATE LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS<br/>[FR] MACROLIDES A LIAISON CARBAMATE UTILISES DANS LE TRAITEMENT DES INFECTIONS MICROBIENNES
申请人:PLIVA ISTRAZIVACKI INST D O O
公开号:WO2005108413A1
公开(公告)日:2005-11-17
The present invention relates to 14- or 15-membered macrolides substituted at the 4' position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.
Ether linked macrolides useful for the treatment of microbial infections
申请人:Alihodzic Sulejman
公开号:US20060258600A1
公开(公告)日:2006-11-16
The present invention relates to 14- or 15-membered macrolides substituted at the 4″ position of formula (I)
and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.
Synthesis, antibacterial activity and pharmacokinetic properties of a novel class of macrolide antibiotics—macrolones—derivedfrom azithromycin, comprising oxygen atom(s) in the linker and either free or esterified quinolone 3-carboxylic group, are reported. Selected compounds showed excellent antibacterial potency towards key erythromycin resistant respiratory pathogens. However, the majority of compounds
[EN] NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES A CYCLES A 14 ET 15 ELEMENTS
申请人:GLAXO GROUP LTD
公开号:WO2004101590A1
公开(公告)日:2004-11-25
The present invention relates to 15-membered macrolides substituted at the 4' position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.
[EN] MACROLIDES SUBSTITUDED AT THE 4"-POSITION<br/>[FR] MACROLIDES SUBSTITUES EN POSITION 4''
申请人:GLAXO GROUP LTD
公开号:WO2004101585A1
公开(公告)日:2004-11-25
The present invention relates to 14- or 15-membered macrolides substituted at the 4' position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.